SK Life Science to Unveil Groundbreaking Epilepsy Research at AAN 2026 At the AAN 2026 Annual Meeting, SK Life Science will present crucial research on cenobamate and insights from epilepsy patient-provider surveys, enhancing understanding of treatment communications.

SK Life Science to Unveil Groundbreaking Epilepsy Research at AAN 2026 #United_States #Chicago #Cenobamate #SK_Life_Science #Epilepsy

This is the first placebo-controlled cenobamate efficacy study to use the globally approved cenobamate titration schedule.
doi.org/10.1111/epi....

#epilepsy #ILAE #epilepsia #antiseizuremedication #efficacy #refractory #titration #cenobamate

SK Life Science to Unveil Groundbreaking Cenobamate Data at 2025 AES Meeting SK Life Science will present ten impactful posters, featuring new data on cenobamate, at the 2025 AES Annual Meeting. Discover groundbreaking findings.

SK Life Science to Unveil Groundbreaking Cenobamate Data at 2025 AES Meeting #United_States #Atlanta #Cenobamate #SK_Life_Science #AES_Meeting

Cenobamate demonstrates sustained seizure freedom and a favorable safety profile in patients with drug-resistant epilepsy.
doi.org/10.1111/epi....

#epilepsy #ILAE #epilepsia #antiepileptic #cenobamate #drugresistantepilepsy #seizurefreedom

SK Life Science Publishes New Research on Cenobamate for Focal Seizures in Asia SK Life Science has released newly published studies analyzing the effectiveness of cenobamate for adult Asian patients with uncontrolled focal seizures, marking significant advances in CNS treatments.

SK Life Science Publishes New Research on Cenobamate for Focal Seizures in Asia #None #Cenobamate #SK_Life_Science #Paramus #Epilepsy

We present the largest series reporting on the off-label use of Cenobamate (CNB) in 16 adults with drug-resistant idiopathic generalized epilepsy, including 12 with JME.
onlinelibrary.wiley.com/doi/10.1002/...

#epilepsy #ilae #epilepsiaopen #antiseizuremedication #Cenobamate #healthcareutilization

Cenobamate achieved seizure response in 83.9%, and seizure freedom in 19.6% at 12 months in 169 Spanish children with drug-resistant epilepsy.
doi.org/10.1111/epi....

#epilepsy #epilepsia #ILAE #antiseizuremedications #cenobamate #DEE #focalseizures #pediatric

Clinicians should rule out contributing etiologies and consider CNB dose reduction if excessive weight loss occurs.
doi.org/10.1111/epi....

#epilepsy #epilepsia #ILAE #antiseizuremedication #weightchange #Cenobamate

A Korean Drug Only Prescribed Abroad, Set to Become Korea’s First Approved New Drug of the Year The Korean-developed epilepsy treatment Cenobamate (marketed in the U.S. as Xcopri), which has already proven its efficacy in the United States and Europe, is

The Korean-developed epilepsy treatment Cenobamate, which has already proven its efficacy in the United States and Europe, is now on the verge of being approved in its home country.
#drug #cenobamate #us #europe #bio #it #itchosun #chosun #SouthKorea #Korea #NewsUpdate

Key point: Several newer antiseizure medications, including the most recent, cenobamate, are now available for the treatment of focal epilepsy.
doi.org/10.1111/epi....

#epilepsy #ILAE #Cenobamate #SKlifescience #antiseizuremedications #drugresistantepilepsy #focalepilepsy

Key point: Evidence supports the consideration of cenobamate earlier in the treatment regimen and suggests a potential new benchmark for ASM treatment.
doi.org/10.1111/epi....

#epilepsy #ILAE #Cenobamate #SKlifescience #antiseizuremedications #epilepsyinolderpatients #pediatricepilepsy

Key point: Tolerability is an essential component of the overall effectiveness of antiseizure medications.
doi.org/10.1111/epi....

#epilepsy #ILAE #Cenobamate #SKlifescience #drugdruginteractions #titration #tolerability

SK Life Science to Present Groundbreaking XCOPRI Data at AAN 2025 Annual Meeting At the 2025 AAN Annual Meeting, SK Life Science will present pivotal research on XCOPRI, highlighting its efficacy in epilepsy management, with real-world insights.

SK Life Science to Present Groundbreaking XCOPRI Data at AAN 2025 Annual Meeting #United_States #San_Diego #Cenobamate #SK_Life_Science #XCOPRI

Key point: Patients included in this EAP had a median history of 22 years of epilepsy, a median of 9 prior failed ASMs, and 41.9% had epilepsy surgery.
doi.org/10.1002/epi4...

#epilepsy #ilae #epilepsiaopen #antiseizuremedication #cenobamate #responderrate #seizurefreedom

Special Issue: Evolving Landscape of Epilepsy Treatment: Focus on Cenobamate
onlinelibrary.wiley.com/toc/15281167...

#epilepsy #ILAE #cenobamate #specialissue

Key point: Cenobamate significantly reduces seizure frequency and shows high retention rates.
doi.org/10.1111/epi....

#epilepsy #ILAE #antiseizuremedications #cenobamate #drugresistantepilepsy #focalseizures #realworld

SK Life Science Unveils Groundbreaking Insights on XCOPRI® at AES 2024 Annual Meeting SK Life Science presented new data on XCOPRI® at the AES 2024 meeting, highlighting its dual mechanism of action offering fresh hope for epilepsy patients.

SK Life Science Unveils Groundbreaking Insights on XCOPRI® at AES 2024 Annual Meeting #United_States #Cenobamate #Epilepsy #Paramus,_New_Jersey #XCOPRI

SK Life Science Showcases Innovative Cenobamate Research at 2024 AES Annual Meeting in Los Angeles SK Life Science is set to present new findings on cenobamate, an anti-seizure medication, at the American Epilepsy Society's Annual Meeting 2024, addressing critical patient treatment needs.

SK Life Science Showcases Innovative Cenobamate Research at 2024 AES Annual Meeting in Los Angeles #United_States #Los_Angeles #Cenobamate #SK_Life_Science #Epilepsy_Society